Welcome to our dedicated page for Petmed Express SEC filings (Ticker: PETS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PetMed Express, Inc. filings document the regulatory record for a Florida public company operating the PetMeds and PetCareRx pet pharmacy businesses. Annual and current reports disclose operating results, non-GAAP reconciliations, intangible-asset impairment matters involving the PCRX trade name, and the financial reporting issues reflected in Forms 12b-25 and Nasdaq continued-listing notices.
Other filings cover governance and capital-structure matters, including annual meeting voting results, director elections, executive compensation advisory votes, audit committee composition, amendments to the shareholder rights agreement, and modifications to security holder rights. The record also includes Form 8-K disclosures for material agreements, board appointments, results releases, and listing compliance communications.
Douglas Krulik, identified as Chief Accounting Officer and a director of PetMed Express, Inc. (ticker: PETS), filed an Initial Statement of Beneficial Ownership (Form 3) reporting the event date of 08/19/2024. The filing states that no securities are beneficially owned by the reporting person. The form indicates it was filed by one reporting person and includes a manual signature dated 09/11/2025. The document provides the reporting person’s business address in Delray Beach, Florida, and confirms compliance with Section 16 reporting requirements through this submission.
PetMed Express, Inc. reported receiving a Nasdaq notice on August 20, 2025 stating it is not in compliance with Nasdaq Listing Rule 5250(c)(1) because it has not yet filed its Annual Report on Form 10-K for the year ended March 31, 2025 and its Quarterly Report on Form 10-Q for the period ended June 30, 2025.
The company has until September 1, 2025 to submit a plan to regain compliance and, if Nasdaq accepts the plan, may be given up to December 29, 2025 to become current in its filings. The notice does not immediately affect the listing of PetMed’s common stock on Nasdaq.
PetMed states it is working diligently to complete and file the delayed reports as promptly as possible so it can regain compliance with Nasdaq’s listing standards.
PetMed Express insider purchase reported. Silvercape Investments Ltd filed a Form 4 showing it acquired 101,000 shares of PETS at $3.17 on 08/13/2025, increasing its direct beneficial ownership to 2,579,696 shares. The filing lists the reporting relationship as Director, shows transaction code P (purchase), and is signed by Peter Kennedy on 08/14/2025.
PetMed Express reported that on August 11, 2025 its Chief Executive Officer and President, Sandra Campos, and its Chief Financial Officer and Treasurer, Robyn D’Elia, resigned effective immediately. Under separation agreements the Company will continue each officer’s annual base salary for 13 months ($550,000 for Ms. Campos; $425,000 for Ms. D’Elia), reimburse COBRA premiums for 18 months, and accelerate pro‑rata vesting of certain restricted stock units while other equity awards will be forfeited. The Board reduced its size from six to five and appointed Leslie C.G. Campbell as Interim CEO and President and Doug Krulik as Interim Principal Financial Officer (while he continues as Chief Accounting Officer). The filing discloses an ongoing Audit Committee investigation into autoship revenue recognition, a $50 coupon promotion, and the company’s control environment; a press release was furnished as Exhibit 99.1.
PetMed Express, Inc. notified the SEC that it cannot timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2025 because the company's Audit Committee investigation described in a Current Report filed July 1, 2025 remains incomplete.
The company says completion of that investigation is required to finish and file its Annual Report for the fiscal year ended March 31, 2025, which must be filed before the 10-Q. PetMed indicates a significant change in results is anticipated but cannot reasonably estimate amounts at this time. Contact: Robert Lawsky, General Counsel.
PetMed Express (PETS) Form 4 filing: On 18 Jul 2025, 10% owner Silvercape Investments Ltd purchased 17,565 common shares at $3.23 each (≈$56.7 k). The move raises its directly held stake to 2,360,496 shares. No sales or derivative transactions were disclosed. While the add-on represents only ~0.7% of the owner’s position, continued buying from a >10% holder can signal confidence without materially altering the share count or control position.
PetMed Express Inc. (PETS) Form 4 filing reports that 10% owner Silvercape Investments Ltd purchased 2,817 common shares on 07 July 02 2025 at $3.22 per share, for an outlay of roughly $9.1 thousand. Following the transaction, Silvercape directly holds 2,311,230 shares of PETS. The purchase increases the investor’s stake by about 0.12%, indicating incremental but limited additional commitment to the company.